# Holos Life Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/holos-life-sciences

- Industry: Biotechnology
- Headquarters: Singapore
- Website: www.holoslifesciences.com
- Total disclosed funding: $1.8M
- Latest round: Series A (Nov 30, 2018)
- Investors on record: 2

## About

Based in Singapore, and established in 2016, Holos Life Sciences is a biotechnology company that focuses on the epigenome biomarker field. It has additional branches in Singapore, Australia, and the UK. Dr. Alexandre Akoulitchev, and Dr. Peter Fricker, the company's founders, are investment professionals. Dr. Alexandre Akoulitchev, the company's chief scientific advisor, majored in cell biology and graduated from University College London.

Holos Life Sciences focuses on R&D of biomarkers for the non-disease state, using the platform EpiSwitch™ developed by Oxford Biodynamics Plc. EpiSwitch™ can discover 3D genomics at scale, and identify chromosome conformation signature biomarkers. The biomarkers have predictive, diagnostic, and prognostic values. The biomarkers can be used for developing human personalized healthcare.

## Funding rounds

- Series A, Nov 30, 2018, $1.8M — Vulpes Investment Management, Oxford Biodynamics Plc

## Investors

- Vulpes Investment Management (https://capitalatlas.ai/funds/vulpes-investment-management) — Series A
- Oxford Biodynamics Plc — Series A